| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |